文献速递肝病消化道肿瘤与早癌

台湾慢性乙型肝炎相关代偿期肝硬化初治患者恩替卡韦或替诺福韦治疗五年肝细胞癌发生风险比较

Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
PubMed 文献 · Aliment Pharmacol Ther · 2020-10-27

基于纵向队列研究,纳入2008年1月至2018年3月894例慢性乙型肝炎相关代偿期肝硬化初治患者,比较恩替卡韦(678例)与富马酸替诺福韦二吡呋酯(216例)治疗5年肝细胞癌累积发生率及危险因素。替诺福韦组5年累积发生率10.7%,恩替卡韦组18.7%(P=0.0305);多因素调整后替诺福韦较恩替卡韦的肝细胞癌风险降低未达统计学显著。

要点

  • 恩替卡韦组5年肝细胞癌累积发生率为18.7%,替诺福韦组为10.7%(P=0.0305)。
  • 血小板计数、甲胎蛋白水平及上消化道静脉曲张为肝细胞癌发生的独立危险因素。
  • 多因素调整后替诺福韦较恩替卡韦的肝细胞癌风险降低未达统计学显著。

核心结论

  • 对于慢性乙型肝炎相关代偿期肝硬化初治患者,5年随访中,经变量调整、倾向性评分方法及亚组分析后,替诺福韦较恩替卡韦显示较低的肝细胞癌发生率,但未达统计学显著。

研究设计与样本

  • 纵向队列研究,纳入2008年1月至2018年3月894例慢性乙型肝炎相关代偿期肝硬化初治患者,其中恩替卡韦组678例、替诺福韦组216例;数据原始收集随访7.3年或至2011年替诺福韦上市后,仅评估5年肝细胞癌累积发生率和危险因素。

主要发现

  • 恩替卡韦组1年、3年、5年肝细胞癌累积风险分别为1.6%、11.3%、18.7%;替诺福韦组分别为0.9%、6.7%、10.7%(P=0.0305)。
  • 单因素及调整多因素模型显示,血小板计数、甲胎蛋白水平及上消化道静脉曲张为肝细胞癌发生的独立危险因素。
  • 在逐步选择、倾向性评分调整和倾向性评分匹配多因素模型中,替诺福韦较恩替卡韦的调整风险比分别为0.66(95%CI:0.40,1.08;P=0.0971)、0.69(95%CI:0.42,1.14;P=0.1488)和0.66(95%CI:0.38,1.14;P=0.1407)。

关键数值与推荐

  • 恩替卡韦组5年肝细胞癌累积发生率为18.7%,替诺福韦组为10.7%(P=0.0305)。
  • 替诺福韦较恩替卡韦的调整风险比在逐步选择模型中为0.66(95%CI:0.40,1.08;P=0.0971)。
  • 替诺福韦较恩替卡韦的调整风险比在倾向性评分调整模型中为0.69(95%CI:0.42,1.14;P=0.1488)。
  • 替诺福韦较恩替卡韦的调整风险比在倾向性评分匹配多因素模型中为0.66(95%CI:0.38,1.14;P=0.1407)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Comparative long-term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) for prevention of disease progression to hepatocellular carcinoma (HCC) among high-risk patients with chronic hepatitis B (CHB)-related compensated cirrhosis is controversial. AIMS: To compare the long-term efficacy of ETV and TDF in HCC prevention in patients with CHB-related cirrhosis, and to evaluate predictive risk factors for HCC development. METHODS: From January 2008 to March 2018, 894 treatment-naïve patients with CHB-related compensated cirrhosis on ETV or TDF were enrolled based on the longitudinal cohort study. Data were originally collected for 7.3 years of follow-up or after the launch of TDF in 2011. Only the 5-year cumulative incidence and risk factors of HCC were assessed. RESULT: Total 678 and 216 patients received ETV and TDF, respectively. The cumulative risk of HCC at 1, 3 and 5 years of follow-up was 1.6%, 11.3% and 18.7%, respectively, in the ETV group; and 0.9%, 6.7% and 10.7%, respectively, in the TDF group (P = 0.0305). Univariate and adjusted-multivariable models revealed that platelet count, alpha-fetoprotein (AFP) levels and upper gastrointestinal (UGI) varices were independent risk factors for HCC development. TDF resulted in risk of HCC development compared to ETV with adjusted hazard ratios (aHRs) of 0.66 (95% confidence interval [CI]:0.40, 1.08; P = 0.0971), 0.69 (95% CI: 0.42, 1.14; P = 0.1488) and 0.66 (95% CI: 0.38, 1.14; P = 0.1407) under stepwise selection, propensity score adjustment, and propensity score matching multivariable models, respectively. CONCLUSIONS: For treatment-naïve patients with CHB-related compensated cirrhosis with 5-year follow-up, after variable adjustments, propensity score approaches and subgroup analyses, TDF showed a lower rate of HCC development that did not reach statistical significance, compared to the ETV.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hu TH, Yueh-Hsia Chiu S, Tseng PL, et al. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan. Aliment Pharmacol Ther. 2020. PMID: 33111400. doi:10.1111/apt.16116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。